ASX-Dividend-Report-Banner
Sponsored

High on 2021 gains, Holista Colltech (ASX:HCT) outlines positive 2022 outlook

June 03, 2022 12:33 PM AEST | By Manisha
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp
 High on 2021 gains, Holista Colltech (ASX:HCT) outlines positive 2022 outlook
Image source: © Demidovichphotostock | Megapixl.com

Highlights

  • Holista Colltech is going strong in the current fiscal year 2022 following a year of achievements.
  • Revenue grew 13% to record AU$8 million, while net loss before tax narrowed significantly in FY21.
  • Sales receipts touched all-time high in the March 2022 quarter with significant growth across divisions.
  • New products, global partnerships and other growth factors are expected to fuel a stronger 2022.

Holista Colltech Limited (ASX:HCT) is an emerging Australian developer of health and wellness products in the US$4.4 trillion global health and wellness industry.

The year 2021 marked a strong rebound for the company with remarkable growth across its business divisions. The strong performance paved the company’s way to a stronger 2022 with great prospects of significant developments in its product portfolio and business expansion worldwide.

  • Dietary Supplements Division- Markets and sells 37 different propriety supplements and owns leading vitamin brands in Malaysia
  • Healthy Food Ingredients Division – Offers clean-label low GI premix called GI LiteTM for healthy breads, noodles and pasta, as well as healthy sugar alternative 80LessTM
  • Infection Control Division – Offers a range of natural and alcohol-free sanitising solutions that have been effective against viruses, including COVID-19
  • Ovine Collagen Division – Only company producing Australian-made sheep collagen that is extracted using a patented process.

2021 – A Year of Achievements

Holista ended the fiscal year 2021 with double-digit growth in three out of four of the divisions. The company’s revenue for FY21 touched record value of AU$8 million, 13% higher than the COVID-19 impacted FY20.

There was strong growth across business units – 18% in Dietary Supplements, 33% in Healthy Food Ingredients and 43% in Olive Collagen. Also, Holista’s newest division of Infection Control saw strong demand for sanitising solutions. 

The solid growth can be attributed to great initiatives and developments at various levels. Have a look! 

Year of achievements
Source: Company announcement

ALSO READ: Holista Colltech scores big, signs initial order for Starbucks and Country Farms

Holista set for a magnificent leap up in 2022

Holista has set the ball rolling for the fiscal year 2022 with a sharp jump in the first quarter of 2022.

The firm posted high quarterly sales receipts worth AU$2.4 million, representing 34% growth on prior comparable period (pcp). The total sales of the company including all the four divisions went up to AU$2.7 million, 42% higher on pcp.

Several growth drivers including new product launches and partnerships are expected to accelerate the ASX-listed company’s growth momentum in 2022.

Furthermore, rising demand for most of Holista’s products in the global market would contribute to its uprearing performance by a great deal in the coming quarters. On this front, the company has been investing heavily in building inventory of raw materials.

Stock information: HCT shares traded at AU$0.031 on 2 June 2022, with market capitalisation of AU$8.53 million.

ALSO READ: Holista’s all-natural disinfectant kills 99.99% of human coronavirus strain, confirms test


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.